Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29972666 | 1.00 | NPC1 (0.36) | NPC1RAB9ASMN1; SMN2KMT2APOLB | |
| SCHEMBL24955122 | 0.80 | MAPK1 (0.53) | NPC1RAB9ASMN1; SMN2KMT2ATDP1 | |
| SCHEMBL29973045 | 0.79 | KDM4E (0.35) | NPC1RAB9ASMN1; SMN2KMT2APOLB | |
| SCHEMBL27082404 | 0.79 | KDM4E (0.35) | NPC1RAB9ASMN1; SMN2KMT2APOLB | |
| SCHEMBL24409131 | 0.75 | HCRTR1 (0.36) | — | |
| SCHEMBL30630767 | 0.75 | HCRTR1 (0.36) | — | |
| SCHEMBL24409344 | 0.75 | CHRNA7 (0.30) | — | |
| SCHEMBL20168157 | 0.74 | HCRTR1 (0.35) | — | |
| SCHEMBL30630851 | 0.72 | HCRTR1 (0.35) | KMT2AMEN1 | |
| SCHEMBL24409132 | 0.72 | HCRTR1 (0.35) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268897-A1 | USE OF HETEROCYCLIC COMPOUND IN TREATING DISEASES RELATED TO KINASE DRUG-RESISTANT MUTATION AND METHOD THEREFOR | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-08-28 | — | — | US | disclosed |
| EP-4316490-A1 | USE OF HETEROCYCLIC COMPOUND IN TREATING DISEASES RELATED TO KINASE DRUG-RESISTANT MUTATION AND METHOD THEREFOR | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2024-02-07 | — | — | EP | disclosed |
| CN-117327078-A | Heterocyclic compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-117263945-A | Heterocyclic compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-113316578-B | Heterocyclic compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116801882-A | Use and method of heterocyclic compounds for treating diseases associated with kinase resistant mutations | 四川科伦博泰生物医药股份有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20220144847-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | ELLIPSES PHARMA LTD (GB) | 2022-05-12 | — | — | US | disclosed |
| CN-113316578-A | Heterocyclic compounds, pharmaceutical compositions containing them, processes for their preparation and their use | 四川科伦博泰生物医药股份有限公司 | 2021-08-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144847-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | NOTUM, FURIN, CYP4A11 | NPC1 497/4885RAB9A 852/4885SMN1; SMN2 2630/4885 |
| US-20250268897-A1 | USE OF HETEROCYCLIC COMPOUND IN TREATING DISEASES RELATED TO KINASE DRUG-RESISTANT MUTATION AND METHOD THEREFOR | RET, VHL, REL | NPC1 1535/4885RAB9A 511/4885SMN1; SMN2 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.